Coding

Part:BBa_K4375006

Designed by: Zska Csorba   Group: iGEM22_ELTE   (2022-09-28)
Revision as of 12:41, 10 October 2022 by NYMP (Talk | contribs)


Anti-CEA Nanobody (C43)

CEA-specific (carcinoembryonic antigen) Nanobody is optimized for production in E. coli. This Nanobody has the ability to bind to the CEA antigen and thus can be used to identify cells over expressing the CEA antigen, which is common in various cancers.


Usage and Biology

Nanobodies are monomeric, single-domain antibody fragments derived from camelids and are useful in therapies due to their small size and specific antigen binding. Nanobodies can be expressed in bacterial systems because unlike antibodies, it has no characteristic post-translational modification like glycosylation. Fused to a cargo they can easily penetrate solid tumors and have the desired effect like killing cells locally. Anti-CEA nanobody is targeting the immunglobulin-like glycoprotein CEA (carcinoembryonic antigen) which is a tumor biomarker in pancreatic cancer (overexpressed in about 85% of pancreatic cancers), but also present in colorectal and lung cancer. Due to its frequency in pancreatic cancer, it is often used as a tumor biomarker. CEA is associated with liver metastasis therefore it is a sign of malignant cancer as well.


Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal PstI site found at 244
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal PstI site found at 244
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal PstI site found at 244
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal PstI site found at 244
  • 1000
    COMPATIBLE WITH RFC[1000]


References

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138244/

Lwin TM, Turner MA, Nishino H, Amirfakhri S, Hernot S, Hoffman RM, Bouvet M. Fluorescent Anti-CEA Nanobody for Rapid Tumor-Targeting and Imaging in Mouse Models of Pancreatic Cancer. Biomolecules. 2022 May 16;12(5):711.

De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends in biotechnology. 2014 May 1;32(5):263-70.

Turner MA, Lwin TM, Amirfakhri S, Nishino H, Hoffman RM, Yazaki PJ, Bouvet M. The use of fluorescent anti-CEA antibodies to label, resect and treat cancers: a review. Biomolecules. 2021 Dec 2;11(12):1819.

Lee JH, Lee SW. The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches. Gastroenterology research and practice. 2017 Oct;2017.

Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung cancer. 2012 May 1;76(2):138-43.



[edit]
Categories
Parameters
None